Research Index
Semaglutide Research Index
PSI surfaces 50 peer-reviewed studies on Semaglutide, prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
Assessment of Carbon Emission Impact of Semaglutide in Patients with Type 2 Diabetes in the United Kingdom using an Innovative Modelling Approach.
Lund N, Rasche A, Taylor M et al.
Value Health·2026·Human·PubMed →
Real-World Impact of Oral Semaglutide on Inflammatory Markers in Patients at High Cardiovascular Risk.
Mariscal Vázquez S, Jiménez-Méndez C, Pérez Asensio A et al.
Rev Clin Esp (Barc)·2026·Human·PubMed →
Semaglutide for treatment of intractable diarrhea of different etiologies: a case series of 30 patients.
Nielsen GL, Hellström PM, Olesen SS et al.
Scand J Gastroenterol·2026·Human·PubMed →
Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.
Cronenberger C, Amin NB, Le VH et al.
J Clin Pharmacol·2026·Human·PubMed →
Euthyroid Sick Syndrome Precipitated By Rapid Weight Loss Following Semaglutide Initiation: A Case Report.
Elmezayen ZW, Qrareya F, Abdallah A et al.
Clin Med Insights Endocrinol Diabetes·2026·Human·PubMed →
Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide.
Vilsbøll T, Arun Kumar D, Aiello LP et al.
Br J Ophthalmol·2026·Human·PubMed →
Semaglutide 2.4 mg Cardiometabolic Long-Term Effects in Patients With Obesity or Overweight in a Real-World Setting: A Retrospective Cohort Study in the United States (SMILE).
Ruseva A, Michalak W, Bassan M et al.
Diabetes Obes Metab·2026·Human·PubMed →
Familial partial lipodystrophy type 2 associated with a novel LMNA variant (c.604G>C; p.Glu202Gln): a Colombian family case series.
Mendoza C, Cano R, Burgos L et al.
Front Endocrinol (Lausanne)·2026·Human·Glycemic Control·PubMed →
Acute Systemic Complications Following High-Dose Semaglutide Reinitiation in an Elderly Patient.
Mehta J, Tai B, Frunzi J
Clin Case Rep·2026·Human·PubMed →
Unexplained hypercapnia with normal pulmonary evaluation in a patient receiving semaglutide: a diagnostic challenge.
Prasad S, Ahuja A, Katwa LC et al.
JCEM Case Rep·2026·Human·PubMed →
Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study).
Kapoor N, Shaikh S, Bhattacharya S et al.
Cardiovasc Diabetol Endocrinol Rep·2026·Human·PubMed →
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients with Type 2 Diabetes and Diabetic Retinopathy.
Shah J, Makwana B, Panchal K et al.
Am J Ophthalmol·2026·Human·PubMed →
Liver benefits of early initiation of low-dose GLP-1 receptor agonists in newly diagnosed type 2 diabetes - A case report.
Lee JY, Nguyen H, Nguyen T
J Family Med Prim Care·2026·Human·PubMed →
LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial.
Alawadhi AA, Alroudhan D, Alsaeed DJ et al.
BMJ Open·2026·Human·Weight Loss, Glycemic Control·PubMed →
Semaglutide-Associated Acute Pancreatitis in a Patient With Type 2 Diabetes Mellitus: A Case Report.
Puri P, Akhavan M, Shadan J et al.
Cureus·2026·Human·PubMed →
Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study.
Corley MJ, Pang APS, Kitch DW et al.
NPJ Aging·2026·Human·PubMed →
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Johansson E, Wilding JPH, Upadhyay N et al.
J Med Econ·2026·Human·Weight Loss, Glycemic Control·PubMed →
Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5.
Galindo RJ, Aronne LJ, Horn DB et al.
J Endocrinol Invest·2026·Human·PubMed →
Glucagon-like peptide-1 receptor agonists (GLP1RA) in the management of mitochondrial diabetes in an adolescent: A Case Report.
Hayes E, Nillsen A, Rowe PW et al.
Horm Res Paediatr·2026·Human·PubMed →
Glucagon-Like Peptide-1 Receptor Agonists in Patients with Heart Failure with Reduced Ejection Fraction.
Kassab J, Drazner MH, Thibodeau JT
ESC Heart Fail·2026·Human·PubMed →
Hemodynamic Changes in Response to GLP-1 Treatment in ICD and CRT Patients: Insights From HeartLogic Sensor Data.
Fussing FH, Davodian LW, Davodian DW et al.
Eur J Heart Fail·2026·Human·PubMed →
Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis.
Zhu X, Wang X, Zhang P et al.
Front Endocrinol (Lausanne)·2026·Human·Glycemic Control·PubMed →
GLP-1 Receptor Agonist Semaglutide and SGLT2 Inhibitors after Acute Coronary Syndrome in Patients with Diabetes: Real-World Comparative Outcomes from an Observational Registry.
Jurin I, Gjuras K, Bešić D et al.
Cardiology·2026·Human·PubMed →
Glucagon-Like Peptide-1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients.
Kutler RB, Lin A, Zhang L et al.
Otolaryngol Head Neck Surg·2026·Human·PubMed →
Real-world use of semaglutide in patients with type 2 diabetes and end-stage renal disease: a multicenter retrospective cohort study.
Alkhezi O, Alfehaid L, Alanezi A et al.
Front Endocrinol (Lausanne)·2026·Human·Glycemic Control·PubMed →
Geriatric Pharmacotherapy Case Series: GLP-1 RA for Weight Management in Older Adults.
Toma L, Buckley K, Early N
Sr Care Pharm·2026·Human·Glycemic Control, Weight Loss·PubMed →
Semaglutide-Associated Sequential Unilateral Transient Osteoporosis of The Hip: A Case Report.
Keles A, Sari K, Giray E et al.
Am J Phys Med Rehabil·2026·Human·PubMed →
The "Ozempic® Limb": Understanding the Impact of Semaglutide on Prosthesis Use and Residual Limb Care in Individuals with Lower Limb Amputation - Case Report.
Bykowski J, Loewen G, Loewen B et al.
Am J Phys Med Rehabil·2026·Human·PubMed →
Real-world glycemic control, exploratory cardiorenal indicators, and safety of polyethylene glycol loxenatide versus semaglutide in type 2 diabetes patients: a Chinese two-center retrospective cohort study.
Yu Z, Fu D, Xu J et al.
Front Endocrinol (Lausanne)·2026·Human·Glycemic Control·PubMed →
Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in indian adults with obesity: A phase III randomized non-inferiority trial.
Sharma PK, Redkar SV, Madhav Karmalkar A et al.
Metabol Open·2026·Human·PubMed →
Semaglutide Induces Changes in Gastric Electrical Activity in Patients With Overweight and Obesity: A Pilot Study.
Abraham R, Foong D, Piya M et al.
J Neurogastroenterol Motil·2026·Human·PubMed →
Preoperative GLP-1 Receptor Agonists and Thromboinflammatory Markers in Patients Undergoing Abdominoplasty: A Prospective Monocentric Study.
Bruno A, Schirosi M, Foti R
Aesthetic Plast Surg·2026·Human·PubMed →
Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.
Savvidou S, Augousti-Varela E, Damianakou A et al.
Metab Syndr Relat Disord·2026·Human·Glycemic Control, Weight Loss, Liver Protection, Liver Fat (MASLD)·PubMed →
Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
Meyhöfer SM, Cariou B, Cercato C et al.
Nat Med·2026·Human·PubMed →
Effect of Semaglutide on Body Weight, Blood Lipid Profile, and Adipokine Status in Obese Patients.
Tyurina AV, Kurochkina NS, Yezhov MV
Kardiologiia·2026·Human·Weight Loss, Glycemic Control·PubMed →
Peripheral Eosinophilia in a Patient With Subacute Watery Diarrhea.
Roldan GA, Dapke K, Reinink A
Gastroenterology·2026·Human·PubMed →
Effects of semaglutide on obstructive sleep apnea risk and outcomes in patients with obesity.
Wu JY, Lin YM, Hsu WH et al.
Ann Am Thorac Soc·2026·Human·Sleep Apnea, Weight Loss, Cardiovascular Risk·PubMed →
Five-year follow-up of incretin-based therapy in a patient with KCNJ11-related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction.
Ohkuma T, Aotani R, Sakamoto W et al.
J Diabetes Investig·2026·Human·PubMed →
Inpatient safety, effectiveness of SGLT2 inhibitors and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study.
Moreno-Pérez Ó, Tejera-Muñoz A, Leiva-Mora N et al.
Cardiovasc Diabetol·2026·Human·PubMed →
Cardiovascular Outcomes and Safety of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Gao W, Cai X, Wang X et al.
Diabetes Metab Syndr Obes·2026·Human·PubMed →
GLP-1 and dual GIP/GLP-1 agonists in obese patients with HFpEF: a systematic review and meta-analysis of RCTs.
Musa EYA, Musa AYA
BMC Cardiovasc Disord·2026·Human·PubMed →
Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide.
Barenbaum SR, Gonzalez A, Verzani Z et al.
Obesity (Silver Spring)·2026·Human·PubMed →
Cardiometabolic and Renal Outcomes in Semaglutide Users with Type 2 Diabetes Achieving Glycemic and Weight Goals: An Observational Cohort Study.
Tan X, Tsai WL, Liang Y et al.
Adv Ther·2026·Animal·PubMed →
National trends in prescription drug expenditures and projections for 2026.
Tichy EM, Rim MH, Tadrous M et al.
Am J Health Syst Pharm·2026·Animal·PubMed →
GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice.
Liskiewicz D, Novikoff A, Khalil A et al.
Nature·2026·Animal·PubMed →
Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial.
Gill H, Badulescu S, Shah H et al.
JAMA Psychiatry·2026·Animal·PubMed →
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review.
Sheth S, Merola JF, Weber BN et al.
JAMA Dermatol·2026·Animal·PubMed →
Use of semaglutide and tirzepatide among people with multiple sclerosis.
Salter A, Novak A, Lancia S et al.
Mult Scler·2026·Animal·PubMed →
Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity.
Ciudin A, Johansson E, Zimner-Rapuch S et al.
Diabetes Obes Metab·2026·Animal·PubMed →
Combination therapy with clinically approved PPARα/δ/γ subtype-selective agonists pemafibrate, seladelpar, and pioglitazone in a 4-week diet-induced early-stage MASLD mouse model.
Honda A, Kamata S, Tanaka R et al.
Biomed Pharmacother·2026·Animal·PubMed →